Zalutumumab in Patients With Non-curable Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

August 31, 2011

Conditions
Head and Neck CancerSquamous Cell Cancer
Interventions
DRUG

Zalutumumab

Individual dose titration weekly i.v doses

OTHER

Control

Best Supportive Care

Trial Locations (82)

Unknown

University Hospital Antwerp, Antwerp

St-Luc University Hospital, Brussels

CHNDRF, Charleroi

"University Hospital", Ghent

University Hospital Leuven, Leuven

Cliniques Saint Pierre, Ottignies

BioCancer, Belo Horizonte

Hospital Erasto Gaertner, Curitiba

Centro Goiano de Oncologia, Goiânia

Hospital Araújo Jorge, Goiânia

Fundação Amaral Carvalho, Jaú

CliniOnco, Porto Alegre

Hospital de Clínicas de Porto Alegre, Porto Alegre

Cepho - Centro de Estudos e pesquisa em Hematologia e Oncologia, Santo André

Santo Andre Diag e Tratamentos, Santo André

Centro de Oncologia - InRad HCFMUSP, São Paulo

Hospital Heliópolis, São Paulo

IBCC - Instituto Brasileiro de Combate ao Câncer, São Paulo

UNIFESP, São Paulo - SP

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

London Regional Cancer Program, London

Princess Margaret Hospital, Toronto

BC Cancer Agency, Vancouver, British Colombia

North-Estonian Regional Hospital, Tallinn

Hôpital Beaujon- department of medical oncology, Clichy

Centre Oscar Lambrette, Lille

Centre Antoine Lacassagne, Nice

Hôpital Tenon - department of medical oncology, Paris

Institut Gustave Roussy, Villejuif

Semmelweis University, Budapest

Uzsoki Hospital Budapest, Budapest

University of Debrecen, Debrecen

Petz Aladár, Győr

Szabolcs-Szatmar-Bereg County Hospital, Nyíregyháza

University of Szeged, Szeged

Markusovszky County Hospital, Szombathely

Szent Borbála County Hospital Oncology Department, Tatabánya

Zala County Hospital, Zalaegerszeg-Pózca

Klaipeda Hospital, Klaipėda

Vilnius University, Vilnius

Beskidzkie Centrum Onkologii, Bielsko-Biala

Samodzielny Publiczny Szpital Kiniczny Nr1, Gdansk

Katedra i Onkologii Collegium, Krakow

Szpital Specjalistyczny im. Rydygiera, Krakow

Centrum Onkologii, Lublin

Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn

Centrum Onkologii - Instytut im. M. Curie-Skłodowskiej, Warsaw

Dolnoslaskie Centrum Onkologii, Wroclaw

Szpital Wojewódzki SP ZOZ, Zielona Góra

Belgorod Regional Oncology Dispensary, Belgorod

Regional Oncology Dispensary, Chelyabinsk

Republican Clinical Oncology Dispensary, Izhevsk

Kursk Regional Oncology Dispencary, Kursk

Kursk Regional Oncology Dispensary, Kursk

City Clinincal Oncology Dispensary #1, Moscow

Moscow Research Institute of Oncology, Moscow

NUZ Semashko Central Clinical Hospital No2 OAO, Moscow

Russian Oncology Research Center n.a. Blokhin, Moscow

GUZ NO Oncology Dispensary, Nizhiy Novgorod

Medical Radiological Research Center, Obninsk

St. Petersburg State Medical University, Saint Petersburg

Sochi Oncology Center, Sochi

Stavropol Regional Clinical Oncology Dispensary, Stavropol

Tula Region Oncology Dispensary, Tula

GUZ Volgograd Region Clinical Oncology Dispensary No1, Volgograd

Voronezh Region Clinical Oncology Dispensary, Voronezh

Institute for Oncology and Radiology, Belgrade

Military Medical Academy, Belgrade

Institute of Oncology Sremska Kamenica, Kamenica

Clinic of Maxillofacial Surgery Nis, Niš

Sahlgrenska University Hospital, Gothenburg

Lund University Hospital, Lund

Musgrove Park Hospital, Taunton

Royal Surrey County, Guildford

Bristol Haematology and Oncology Centre, Bristol

The Beatson West of Scotland Centre, Glasgow

Royal Marsden Hospital, London

Christie Hospital, Manchester

Newcastle General Hospital, Newcastle

Weston Park Hospital, Sheffield

New Cross Hospital, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genmab

INDUSTRY

NCT00382031 - Zalutumumab in Patients With Non-curable Head and Neck Cancer | Biotech Hunter | Biotech Hunter